New Formulation Of Medication For Rare Disease Patients
May 15th 2008Drug InformationBlood
A new treatment option - Ferriprox Oral Solution - is now available to patients suffering from thalassaemia major, a rare genetic disease with only 50 percent of the patients surviving the age of 35 years1. Thalassaemia patients require blood transfusions to survive, which leads to damaging iron accumulation in the tissues, especially the heart. Ferriprox (deferiprone) is an iron chelator that effectively removes the excess iron from the body caused by blood transfusions.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
